IP Library › Granted Patent US 12,410,236
Granted Patent B2
US 12,410,236 · App. 18/318,343 · Granted Sep 9, 2025

Compositions comprising PCSK9-binding molecules and methods of use

Inventors: Tracy S. Mitchell (Cincinnati, OH); Richard Mealey (Cincinnati, OH)
Assignee: LIB Therapeutics, Inc.
C07K14/78A61P3/06C07K14/765C07K16/40A61K38/00C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,236
App. No.
18/318,343
Granted
Sep 9, 2025
Kind
B2
Abstract

The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).

Claims (8)

1. A proprotein convertase subtilisin kexin type 9 (PCSK9)-binding fusion protein comprising the amino acid sequence of SEQ ID NO: 3.

2. A composition comprising the PCSK9-binding fusion protein of claim 1 , wherein the concentration of the fusion protein is at least 200 mg/mL.

3. The composition of claim 2 , wherein the concentration of the fusion protein is at least 250 mg/mL.

4. The composition of claim 2 , wherein the concentration of the fusion protein is at least 300 mg/mL.

5. A proprotein convertase subtilisin kexin type 9 (PCSK9)-binding fusion protein consisting of the amino acid sequence of SEQ ID NO: 3.

6. A composition comprising the PCSK9-binding fusion protein of claim 5 , wherein the concentration of the fusion protein is at least 200 mg/mL.

7. The composition of claim 6 , wherein the concentration of the fusion protein is at least 250 mg/mL.

8. The composition of claim 6 , wherein the concentration of the fusion protein is at least 300 mg/mL.

Assignments (1)
CHANGE OF NAME Recorded Sep 5, 2023
From: LIB THERAPEUTICS, LLC
To: LIB THERAPEUTICS, INC.
Reel/Frame 064807/0308 →
Continuity (5)
Continuation 16934816 · Jul 21, 2020
Continuation 16578102 · Sep 20, 2019
Continuation PCTUS2019032710 · May 16, 2019
Provisional Application 62672187 · May 16, 2018
Related Publication 20230295270A1 · Sep 21, 2023
References Cited (21)
US 7932268B2 · Rader · 2011 [cited by examiner]
US 8420098B2 · Camphausen et al. · 2013 [cited by applicant]
US 9234027B2 · Camphausen et al. · 2016 [cited by applicant]
US 9856309B2 · Camphausen et al. · 2018 [cited by applicant]
US 10738102B2 · Mitchell · 2020 [cited by examiner]
US 10947297B2 · Camphausen · 2021 [cited by examiner]
US 11692021B2 · Mitchell · 2023 [cited by examiner]
US 20120094909A1 · Camphausen · 2012 [cited by examiner]
US 20130302399A1 · Feldhaus et al. · 2013 [cited by applicant]
US 20160159883A1 · Camphausen et al. · 2016 [cited by applicant]
US 20180105575A1 · Pabst et al. · 2018 [cited by applicant]
WO WO2011130354A1 · 2011 [cited by examiner]
WO 2014140210A1 · 2014 [cited by applicant]
WO 2014165093A2 · 2014 [cited by applicant]
WO 2015143199A1 · 2015 [cited by applicant]
WO WO2015143156A1 · 2015 [cited by examiner]
Tracy Mitchell et al., Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering, the Journal of Pharmacology and Experimental Therap… [cited by applicant]
M.H. Parker et al., Antibody Mimics Based on Human Fibronectin Type Three Domain Engineered for Thermostability and High-Affinity Binding to Vascular Endothelial Growth Factor Receptor Two, Protien Engineering, Design &… [cited by applicant]
Frederick J. Raal et al., PCSK9 Inhibition-Mediated Reduction in Lp(a) with Evolocumab: An Analysis of 10 Clinical Trials and the LDL Receptor's Role, Journal of Lipid Research vol. 57, 2016, pp. 1086-1096, published by… [cited by applicant]
Esha Sachdev et al., Adnectin-Targeted Inhibitors: Rationale and Results, Curr Oncol Rep (2015) 17:35, published online: Jun. 5, 2015, by Springer Science+Business Media. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/032710 dated Sep. 11, 2019. [cited by applicant]